


PHENOSENSE HIV ENTRY ASSAY

ENVELOPE EXPRESSION VECTOR: pHIVenv



HIV-1 EXPRESSION VECTOR: pHIVlucΔU3




FIG.1A

PHENOSENSE™ HIV: CELL ASSAY




FIG.1B

HIV ENVELOPE EXPRESSION STRATEGIES




FIG.2

CO-RECEPTOR TROPISM SCREEN

CCR5-EXpressing CELLS





FIG.3A



CO-RECEPTOR TROPISM ASSAY INTERPRETATION




FIG.3B

ENTRY INHIBITOR SUSCEPTIBILITY: FUSION INHIBITOR





FIG.4A



REDUCED SUSCEPTIBILITY: FUSION INHIBITOR






FIG.4B



ENTRY INHIBITOR SUSCEPTIBILITY: CCR5 INHIBITOR




DRUG: R5 INHIBITOR

CELL: CD4/CCR5

FIG.5A







DRUG: X4 INHIBITOR
CELL: CD4/CXCR4

FIG.5B




ENVELOPE SEQUENCE AMPLIFICATION



1	2	3	4	5	6	1	2	3	4	5	6	# of isolates
Co-Receptor Tropism												
X4												15
R5												24
X4/R5												15
Undefined												35

Envelope Subtype	# of isolate
Clade A	2
Clade B	76
Clade C	7
Clade D	1
Clade E	3

FIG.6





TARGET CELL RECEPTOR AND CO-RECEPTOR EXPRESSION









FIG.7 CXCR4+CCR5 CELLS

CD4⁺ CCR5⁺ CELLS

CD4⁺ CXCR4⁺ CELLS

INHIBITION BY CO-RECEPTOR ANTAGONISTS









FIG.8



FUSION INHIBITOR PEPTIDES




FIG.9

